Press releases

The shareholders in Chordate Medical Holding AB (publ), 556962-6319, are hereby given notice of the annual general meeting to be held on Wednesday 21 May...
Chordate Medical Holding AB (Publ) has today published its annual report for the fiscal year 2024. The annual report is available on Chordate's website...
Chordate Medical Holding AB announces that the United States Patent and Trademark Office (USPTO) has decided to grant registration of Chordate’s...
Svenska Dagbladet highlights Chordate Medical’s migraine treatment Ozilia in a new feature – and meets one of the first Swedes to try the method...
Summary of the period October–December 2024 Summary of the period January–December 2024 COMMENTS FROM CEO ANDERS WEILANDT Market breakthrough...
Chordate Medical Holding AB (publ) ("Chordate" or the "Company") has entered into a liquidity provider agreement for the Company's...
Chordate Medical Holding has received approval for the listing of its preference share on Nasdaq First North Growth Market, with the first trading day...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, HONG KONG, NEW ZEALAND...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, HONG KONG, NEW ZEALAND...
The subscription period for Chordate Medical’s ongoing rights issue runs until Monday, February 17, 2025. However, some banks may close the subscription...

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the treatment Ozilia®, which is based on Kinetic Oscillation Stimulation, a technique for treating chronic migraine and chronic rhinitis. We have a patent on Ozilia® in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact